Protein Arginine Methyltransferases: Promising Targets for Cancer Therapy

Overview

Journal Exp Mol Med

Specialties Biochemistry
Molecular Biology

Date 2021 May 19

PMID 34006904

Citations 85

Authors

Jee Won Hwang

Yena Cho

Gyu-Un Bae

Su-Nam Kim

Yong Kee Kim

Affiliations

Soon will be listed here.

Abstract

Protein methylation, a post-translational modification (PTM), is observed in a wide variety of cell types from prokaryotes to eukaryotes. With recent and rapid advancements in epigenetic research, the importance of protein methylation has been highlighted. The methylation of histone proteins that contributes to the epigenetic histone code is not only dynamic but is also finely controlled by histone methyltransferases and demethylases, which are essential for the transcriptional regulation of genes. In addition, many nonhistone proteins are methylated, and these modifications govern a variety of cellular functions, including RNA processing, translation, signal transduction, DNA damage response, and the cell cycle. Recently, the importance of protein arginine methylation, especially in cell cycle regulation and DNA repair processes, has been noted. Since the dysregulation of protein arginine methylation is closely associated with cancer development, protein arginine methyltransferases (PRMTs) have garnered significant interest as novel targets for anticancer drug development. Indeed, several PRMT inhibitors are in phase 1/2 clinical trials. In this review, we discuss the biological functions of PRMTs in cancer and the current development status of PRMT inhibitors in cancer therapy.

Citing Articles

Overcoming drug resistance in castrate-resistant prostate cancer: current mechanisms and emerging therapeutic approaches.

Khorasanchi A, Hong F, Yang Y, Singer E, Wang P, Li M Cancer Drug Resist. 2025; 8:9.

PMID: 40051495 PMC: 11883235. DOI: 10.20517/cdr.2024.173.

CARM1 regulates tubulin autoregulation through PI3KC2α R175 methylation.

Cho Y, Hwang J, Bedford M, Song D, Kim S, Kim Y Cell Commun Signal. 2025; 23(1):120.

PMID: 40045375 PMC: 11884010. DOI: 10.1186/s12964-025-02124-z.

Protein Arginine Methyltransferase 1: A Multi-Purpose Player in the Development of Cancer and Metabolic Disease.

de Korte D, Hoekstra M Biomolecules. 2025; 15(2).

PMID: 40001488 PMC: 11852820. DOI: 10.3390/biom15020185.

Prostate Cancer: De-regulated Circular RNAs With Efficacy in Preclinical Models.

Weidle U, Birzele F Cancer Genomics Proteomics. 2025; 22(2):136-165.

PMID: 39993805 PMC: 11880926. DOI: 10.21873/cgp.20494.

S-Adenosylmethionine: A Multifaceted Regulator in Cancer Pathogenesis and Therapy.

Fernandez-Ramos D, Lopitz-Otsoa F, Lu S, Mato J Cancers (Basel). 2025; 17(3).

PMID: 39941901 PMC: 11816870. DOI: 10.3390/cancers17030535.

References

Paik W, Kim S . Enzymatic methylation of protein fractions from calf thymus nuclei. Biochem Biophys Res Commun. 1967; 29(1):14-20. DOI: 10.1016/0006-291x(67)90533-5. View

Yang Y, Bedford M . Protein arginine methyltransferases and cancer. Nat Rev Cancer. 2012; 13(1):37-50. DOI: 10.1038/nrc3409. View

Guccione E, Richard S . The regulation, functions and clinical relevance of arginine methylation. Nat Rev Mol Cell Biol. 2019; 20(10):642-657. DOI: 10.1038/s41580-019-0155-x. View

Blanc R, Richard S . Arginine Methylation: The Coming of Age. Mol Cell. 2017; 65(1):8-24. DOI: 10.1016/j.molcel.2016.11.003. View

Bedford M, Clarke S . Protein arginine methylation in mammals: who, what, and why. Mol Cell. 2009; 33(1):1-13. PMC: 3372459. DOI: 10.1016/j.molcel.2008.12.013. View

Schapira M, Ferreira de Freitas R . Structural biology and chemistry of protein arginine methyltransferases. Medchemcomm. 2015; 5(12):1779-1788. PMC: 4655611. DOI: 10.1039/c4md00269e. View

Tewary S, Zheng Y, Ho M . Protein arginine methyltransferases: insights into the enzyme structure and mechanism at the atomic level. Cell Mol Life Sci. 2019; 76(15):2917-2932. PMC: 6741777. DOI: 10.1007/s00018-019-03145-x. View

Lee H, Kim S, Paik W . S-adenosylmethionine: protein-arginine methyltransferase. Purification and mechanism of the enzyme. Biochemistry. 1977; 16(1):78-85. DOI: 10.1021/bi00620a013. View

Zurita-Lopez C, Sandberg T, Kelly R, Clarke S . Human protein arginine methyltransferase 7 (PRMT7) is a type III enzyme forming ω-NG-monomethylated arginine residues. J Biol Chem. 2012; 287(11):7859-70. PMC: 3318701. DOI: 10.1074/jbc.M111.336271. View

10.

Pawlak M, Scherer C, Chen J, Roshon M, Ruley H . Arginine N-methyltransferase 1 is required for early postimplantation mouse development, but cells deficient in the enzyme are viable. Mol Cell Biol. 2000; 20(13):4859-69. PMC: 85937. DOI: 10.1128/MCB.20.13.4859-4869.2000. View

11.

Yadav N, Lee J, Kim J, Shen J, Hu M, Aldaz C . Specific protein methylation defects and gene expression perturbations in coactivator-associated arginine methyltransferase 1-deficient mice. Proc Natl Acad Sci U S A. 2003; 100(11):6464-8. PMC: 164469. DOI: 10.1073/pnas.1232272100. View

12.

Tee W, Pardo M, Theunissen T, Yu L, Choudhary J, Hajkova P . Prmt5 is essential for early mouse development and acts in the cytoplasm to maintain ES cell pluripotency. Genes Dev. 2010; 24(24):2772-7. PMC: 3003195. DOI: 10.1101/gad.606110. View

13.

Vanlieshout T, Ljubicic V . The emergence of protein arginine methyltransferases in skeletal muscle and metabolic disease. Am J Physiol Endocrinol Metab. 2019; 317(6):E1070-E1080. DOI: 10.1152/ajpendo.00251.2019. View

14.

Hashimoto M, Murata K, Ishida J, Kanou A, Kasuya Y, Fukamizu A . Severe Hypomyelination and Developmental Defects Are Caused in Mice Lacking Protein Arginine Methyltransferase 1 (PRMT1) in the Central Nervous System. J Biol Chem. 2015; 291(5):2237-45. PMC: 4732207. DOI: 10.1074/jbc.M115.684514. View

15.

Yoshimatsu M, Toyokawa G, Hayami S, Unoki M, Tsunoda T, Field H . Dysregulation of PRMT1 and PRMT6, Type I arginine methyltransferases, is involved in various types of human cancers. Int J Cancer. 2010; 128(3):562-73. DOI: 10.1002/ijc.25366. View

16.

Shailesh H, Zakaria Z, Baiocchi R, Sif S . Protein arginine methyltransferase 5 (PRMT5) dysregulation in cancer. Oncotarget. 2019; 9(94):36705-36718. PMC: 6291173. DOI: 10.18632/oncotarget.26404. View

17.

Smith E, Zhou W, Shindiapina P, Sif S, Li C, Baiocchi R . Recent advances in targeting protein arginine methyltransferase enzymes in cancer therapy. Expert Opin Ther Targets. 2018; 22(6):527-545. PMC: 6311705. DOI: 10.1080/14728222.2018.1474203. View

18.

Jarrold J, Davies C . PRMTs and Arginine Methylation: Cancer's Best-Kept Secret?. Trends Mol Med. 2019; 25(11):993-1009. DOI: 10.1016/j.molmed.2019.05.007. View

19.

Bannister A, Kouzarides T . Regulation of chromatin by histone modifications. Cell Res. 2011; 21(3):381-95. PMC: 3193420. DOI: 10.1038/cr.2011.22. View

20.

Zhao Z, Shilatifard A . Epigenetic modifications of histones in cancer. Genome Biol. 2019; 20(1):245. PMC: 6868810. DOI: 10.1186/s13059-019-1870-5. View